Multiple sclerosis is an autoimmune condition that affects your central nervous system. The condition causes your immune system to attack the myelin cells, the protective sheaths surrounding your ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

Background Previous natural history studies highlighted a consistent heterogeneity of disability trajectories among ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine ...

The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing ...

The researchers suggest clinicians might tailor their approach to account for Asian Americans' younger average age when they ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 ...

Alberto Ascherio and Stephen Hauser were recognized for their work uncovering the role of B cells and Epstein Barr virus in ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 ...

“Heather's story,” Mack continued, “from the onset of her symptoms over 10 years ago, to her diagnosis, to where she is at today with her MS, is relatable to many and will inspire others who ...